Charles River Laboratories International (CRL) News Today

Charles River Laboratories International, Inc. (NYSE:CRL) saw its shares climb as the company raised full-year guidance and several analysts lifted price targets. Offsetting some of the gains were mixed Q2 results and an insider stock sale.

• Positive Sentiment: Company raised FY 2025 EPS guidance to $9.90–10.30 (vs. $9.60 consensus) and revenue guidance to $3.9–4.0 billion (vs. $3.9 billion consensus). FY 2025 Guidance
• Positive Sentiment: Evercore ISI raised its price target from $180.00 to $190.00 and kept an “outperform” rating. Evercore ISI Rating
• Neutral Sentiment: JPMorgan Chase & Co. lifted its price target to $160.00 (from $145.00) but maintained a “neutral” rating. JPMorgan Chase & Co. Note
• Neutral Sentiment: Barclays boosted its target to $165.00 (from $155.00) and reiterated an “equal weight” rating. Barclays Note
• Neutral Sentiment: Q2 revenues beat expectations but EPS of $1.06 missed street forecasts. Q2 2025 Earnings
• Negative Sentiment: EVP Joseph W. Laplume sold 400 shares at an average price of $150.04, trimming his holdings by 1.58%. Insider Sale Filing
• Negative Sentiment: Earnings call transcript confirms the EPS shortfall of $1.06 vs. $2.50 expected. Call Transcript